AI Article Synopsis
- Male breast cancer (BC) is uncommon, accounting for under 1% of cases in the U.S., and treatment guidelines are mainly adapted from female BC research.
- Standard care for estrogen receptor-positive (ER+) female BC includes endocrine therapies like selective estrogen receptor modulators, aromatase inhibitors, and anti-estrogens, but male ER+ BC treatments are less understood.
- A case study of a 28-year-old man with metastatic androgen receptor-positive (AR+), ER+ breast cancer highlights successful treatment through hormonal suppression using Letrozole and Leuprolide, showing promising results despite chemotherapy resistance.
Article Abstract
Male breast cancer (BC) is relatively rare, making up less than 1% of all breast cancer cases in the United States. Treatment guidelines for male BC are derived from studies on the treatment of female BC, and are based molecular and clinical characteristics, such as hormone receptor positivity. For female estrogen receptor positive (ER+) breast cancers, the standard of care includes three classes of endocrine therapies: selective estrogen receptor modulators, aromatase inhibitors, and pure anti-estrogens. In contrast to female ER+ breast cancers, there is less known about the optimal treatment for male ER+ BC. Furthermore, in contrast to ER, less is known about the role of the androgen receptor (AR) in male and female BC. We report here the treatment of a 28-year-old man with metastatic AR+, ER+ breast cancer otherwise refractory to chemotherapy, who has had a durable clinical response to hormonal suppression with the combination of aromatase inhibition (Letrozole) in conjunction with a GnRH agonist (Leuprolide).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.critrevonc.2015.11.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!